Related Experiment Video
Updated: Mar 14, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Undiagnosed connective tissue diseases: High prevalence in pulmonary arterial hypertension patients
Lorenzo Cavagna1, Veronica Codullo, Stefano Ghio
1aDivision of Rheumatology bDepartment of Cardiology, University and IRCCS Foundation Policlinico S. Matteo, Pavia cEpidemiology Unit, Italian Society for Rheumatology, Milan, Italy.
Insights
A significant number of patients initially diagnosed with idiopathic pulmonary arterial hypertension (PAH) actually have undiagnosed connective tissue diseases (CTDs). Early rheumatological assessment is crucial, particularly for those with Raynaud phenomenon, due to the poor prognosis associated with Systemic Sclerosis-PAH.
Area of Science:
- Cardiology
- Rheumatology
- Pulmonology
Background:
- Pulmonary arterial hypertension (PAH) subgroups, especially those linked to connective tissue diseases (CTDs), exhibit distinct clinical and prognostic profiles.
- Accurate etiological diagnosis is essential for appropriate management of PAH patients.
Purpose of the Study:
- To determine the frequency of previously undiagnosed CTDs in patients suspected of having idiopathic PAH (iPAH).
- To evaluate the prognostic impact of CTDs in PAH patients.
Main Methods:
- Consecutive PAH patients without prior rheumatological assessment underwent comprehensive CTD evaluation (clinical, laboratory, instrumental).
- Survival analysis was performed for different etiological subgroups (iPAH, CTD-PAH, Systemic Sclerosis-PAH).
Main Results:
- 34.7% of the iPAH cohort were diagnosed with CTD-PAH.
- Antinuclear antibody (ANA) positivity showed high sensitivity and specificity for CTD-PAH.
- Raynaud phenomenon (RP) was highly specific for Systemic Sclerosis (SSc)-PAH.
- Mortality was significantly higher in SSc-PAH patients compared to iPAH patients.
Conclusions:
- A substantial prevalence of undiagnosed CTDs exists within the iPAH population.
- Rheumatological assessment is vital for PAH patients, especially those presenting with RP.
- Systemic Sclerosis-associated PAH carries a particularly unfavorable prognosis, underscoring the need for early identification and management.
Abstract:
Among different subgroups of pulmonary arterial hypertension (PAH), those associated with connective tissue diseases (CTDs) have distinct hemodynamic and prognostic features; a correct etiologic diagnosis is thus mandatory.To estimate frequency and prognosis of previously undiagnosed CTDs in a suspect idiopathic (i) PAH cohort.Consecutive patients with PAH confirmed by right heart catheterization referred at the Cardiology Division of our Hospital without a previous rheumatological assessment or the occurrence of other conditions explaining PAH were checked for CTD by a clinical, laboratory, and instrumental evaluation. Survival in each group has also been analyzed.In our study 17 of 49 patients were classified as CTD-PAH, corresponding to a prevalence (95% CI) of 34.7% (21.7-49.6%). ANA positivity had 94% (71.3-99.9%) sensitivity and 78.1% (60-90.7%) specificity for a diagnosis of CTD-PAH; Raynaud phenomenon (RP) showed 83.3% (51.6-97.9%) sensitivity and 100% (90.5-100%) specificity for the diagnosis of Systemic Sclerosis (SSc)-PAH. At diagnosis, SSc patients were older and had a lower creatinine clearance compared with iPAH and other CTD-PAH. After a median follow-up of 44 (2-132) months, 18 of 49 (36.7%) patients died: 31.2% in the iPAH group, 20% in the CTD-, and 58.3% in the SSc-PAH group. Mortality was significantly higher in SSc-PAH (HR 3.32, 1.11-9.95, P <0.05) versus iPAH.We show a high prevalence of undiagnosed CTDs in patients with iPAH without a previous rheumatological assessment. All patients with RP were diagnosed with SSc. Our data stress the importance of a rheumatological assessment in PAH, especially because of the unfavorable prognostic impact of an associated SSc.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease I: Introduction
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

